10-K/A: Femasys Inc. Files Amended 10-K to Include Omitted Information and Updated Certifications

Femasys Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and updated certifications.

Summary

• Femasys Inc. filed an amendment to its annual report on Form 10-K, designated as Form 10-K/A, to include information previously omitted from the original filing.
• The amendment includes information required by Items 10 through 14 of Part III of Form 10-K, which covers details about directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.
• The company also updated Item 15 of Part IV of the original 10-K to include current certifications as required by the Sarbanes-Oxley Act of 2002.
• The original 10-K was filed on March 28, 2024, and this amendment was filed on April 26, 2024.
• The amendment does not include any new financial statements or modify disclosures affected by subsequent events.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, but the need for an amendment suggests a minor oversight. The company appears to be operating within standard governance practices, but the capital raise and ownership by PharmaCyte Biotech are notable.

Positives

• The company has a well-defined corporate governance structure with an independent audit committee.
• The company has a clawback policy in place to recover incentive-based compensation in the event of financial restatements.
• The company provides a 401(k) retirement savings plan and other benefits to its employees.
• The company has a related person transaction policy to ensure fair dealings.
• The company has a diverse board of directors with experience in various industries.

Negatives

• The company had to file an amendment to its annual report due to the omission of required information.
• The company had a late filing of a Section 16(a) report for Ms. Thomas.
• The company's related person transaction policy was adopted after some of the transactions described in the document occurred.

Risks

• The company's reliance on key personnel, such as the CEO, could pose a risk if there are changes in management.
• The company's financial performance could be impacted by changes in the regulatory environment.
• The company's stock price could be affected by market conditions and investor sentiment.
• The company's future success depends on the successful development and commercialization of its products.

Future Outlook

This amendment does not reflect events occurring after the filing of the Original 10-K or modify disclosures affected by subsequent events.

Management Comments

• Dov Elefant, Chief Financial Officer, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact.
• Kathy Lee-Sepsick, Chief Executive Officer and President, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact.

Industry Context

This filing is a standard regulatory requirement for public companies and provides transparency to investors regarding the company's governance, executive compensation, and financial oversight. The medical device industry is highly regulated, and companies must adhere to strict reporting standards.

Comparison to Industry Standards

• The director compensation structure, including annual retainers and equity awards, is consistent with industry standards for publicly traded medical device companies.
• The executive compensation packages, including base salaries, bonuses, and stock options, are comparable to those of similar-sized companies in the biotechnology and medical device sectors.
• The company's audit committee structure and responsibilities align with best practices for corporate governance.
• The clawback policy is a standard practice for public companies to ensure accountability of executive officers.
• The company's reliance on external auditors, such as KPMG, is typical for publicly traded companies.

Related Party Transactions

• The company employs the daughter of Ms. Lee-Sepsick, with total compensation and benefits less than $150,000 in 2023.
• In November 2023, the company issued convertible notes and warrants to PharmaCyte Biotech, Inc., a significant shareholder, and appointed Joshua Silverman, the interim CEO, President and Director of PharmaCyte Biotech, Inc., to the company's board of directors.

Stakeholder Impact

• Shareholders are provided with updated information regarding the company's governance and executive compensation.
• Employees are provided with information regarding their benefits and compensation.
• Customers and suppliers are not directly impacted by this filing.

Next Steps

• The company will continue to operate under its current governance structure.
• The company will continue to develop and commercialize its medical devices.
• The company will continue to comply with all regulatory requirements.

Key Dates

Keywords

Femasys, 10-K, Amendment, Directors, Executive Compensation, Corporate Governance, Audit Committee, Sarbanes-Oxley, Financial Reporting, Stock Options, PharmaCyte Biotech